

Date Issued: April, 2003 Supersedes the MSDS dated: September, 1998

1. COMPANY & PRODUCT IDENTIFICATION

Manufacturer Name: Takeda Chemical Industries Limited, Osaka, Japan,

for TAP Pharmaceutical Products Inc.

Address:

675 North Field Drive, Lake Forest, IL 60045

Phone:

1-800-622-2011 (Medical Information/Pharmacovigilance)

Product Name:

Sterile Diluent Lupron Depot

Chemical Name:

Not applicable

CAS* Number:

Not applicable

2. COMPOSITION/INFORMATION ON INGREDIENTS

Name/Hazardous* Ingredient	Quantity per	Exposure limits	
*****	2 mL Ampule	OSHA-PEL**	ACGIH-TLV***
d-mannitol (CAS # 69-65-8)	100 mg	Not determined	Not determined

^{*} Hazardous per OSHA criteria

3. HAZAROS/ACUTE EXPOSURE INFORMATION

<u>Emergency Overview</u>: This material is a diluent for Lupron Depot. It does not contain leuprolide acetate. Has a low order of toxicity. Based on d-mannitol as the major ingredient, kidneys and eyes are the target organs. Hypersensitivity to d-mannitol may be observed in some individuals.

<u>Primary Routes of Exposure</u>: These have not been determined but based on the dosage form and limited usage the following are an estimation.

Oral: not likely;

Dermal: rare;

Inhalation: not likely

Acute Toxicity:

Oral:

Not determined for the product. LD₅₀ for d-manmtol is

13,500 to 22,000 mg/kg in mice and rats. Ingestion of large quantities of d-mannitol can cause diarrhea with fluid loss

and electrolyte imbalance.

Dermal: Inhalation: Not determined Not determined

^{*} Chemical Abstract Service

^{**} US Occupational Safety and Health Administration-Permissible Exposure Limit

^{***} American Conference of Governmental Industrial Hygienists- Threshold Limit Value



Date Issued: April, 2003

Supersedes the MSDS dated: September, 1998

OTHER HAZARD INFORMATION:

<u>Dermal Irritation</u>: Not determined <u>Eye Irritation</u>: Not determined Skin Sensitization: Not determined

Likely Target Organs: Eyes and kidneys (based on the osmotic diuretic effect of

d-mannitol)

Miscellaneous: Pre-existing kidney or ocular ailments may be aggravated by

exposure.

a. First aid measures

Eve: Remove from the source of exposure. Flush eyes with copious amounts of

water. If irritation or redness persists, consult a physician.

Skin: Remove from the source of exposure. Flush the area of contact with copious

amounts of water. If irritation persists, consult a physician,

<u>Inhalation</u>: Remove from the source of exposure. If difficulty in breathing, provide artificial respiration (if suitable help available). Seek appropriate medical

attention.

<u>Ingestion</u>: Remove from the source of exposure. If signs of toxicity occur seek medical attention. Provide symptomatic/supportive care if available.

Note to the Physician: No specific antidotal treatment available. Treat symptomatically. Monitor fluid and electrolytes, if indicated. Pre-existing kidney or ocular ailments may be aggravated.

5. FIRE FIGHTING MEASURES

NFPA* Rating: 1: Health, 0: Flammability, 0: Reactivity

Flammability Class: Not flammable
Flash Point: Not applicable
Explosive Limits: Not applicable

Extinguishing Media: No special requirements

Special Protective Equipment: Firefighters should wear full protective

clothing including self-contained breathing equipment.

Fire Fighting Procedures: Normal procedures.
Combustion Products: Not determined

Unusual Fire or

Explosion Hazards: None known

^{*} National Fire Prevention Association



Date Issued: April, 2003

Supersedes the MSDS dated: September, 1998

6. ACCIDENTAL RELEASE MEASURES

Steps to be Taken:

In case of a spill use normal cleaning procedures.

Absorbents:

Clay granules, saw dust, dirt or equivalent.

Incompatibilities:

Not determined.

7. HANDLING PRECAUTIONS

Handling (Personnel): Use standard safety precautions. Avoid contact with

eyes and skin. Safety glasses, gloves or lab coat may be

worn during an excessive exposure situation.

Storage Precautions:

Store according to label instructions.

8. EXPOSURE CONTROL/PERSONAL PROTECTION

Exposure Limits:

Not established

Ventilation:

Standard ventilation is adequate

Personal Protective Equipment: Wear standard laboratory clothes, such as, lab coat,

safety glasses or gloves when a major spill or exposure

is expected.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance (color, etc.):

Clear liquid in 2 mL ampules

Odor:

None

Vapor Density(Air =1):

Not known

Vapor Pressure (mm Hg):

Not known

Solubility in Water: Specific Gravity: Fully miscible 1.0

ι Hα

5 to 7 (per label)

10. STABILITY AND REACTIVITY

Stability:

Stable

Hazardous Polymerization:

Not expected to occur

Incompatibility with other

Materials:

Not determined

Decomposition Products:

Not determined



Date Issued: April, 2003 Supersedes the MSDS dated: September, 1998

11. OTHER TOXICOLOGICAL INFORMATION

Chronic Toxicity:

Not determined /available

Mutagenicity/Carcinogenicity:

Has been referenced (RETECS*) as negative for carcinogenicity (in mouse and rat) per EPA's

(for d-mannitol) for carcinogenicity (in n Genetox program 1988.

Negative per NTP** (NTP TR -236.82) also.

* Registry of Toxic Effects of Chemical Substances

** National Toxicology Program

12. ENVIRONMENTAL/ECOLOGICAL INFORMATION

ENVIRONMENTAL FATE:

Hydrolysis:

Not available

Photolysis:

Not available

Soil half-life:

Not available

ECOTOXICITY:

Acute Toxicity -Fish:

Not determined

Acute Toxicity-

aquatic invertebrates: Not determined

13. DISPOSAL PROCEDURES

Waste resulting from use of this product may be disposed of as a pharmaceutical waste.

14. TRANSPORTATION AND SHIPPING INFORMATION

DOT/ 49CFR Description:

Not applicable

Freight Classification:

Pharmaceutical Product



Date Issued: April, 2003 Supersedes the MSDS dated: September, 1998

15. REGULATORY INFORMATION

SARA* 311/312

Hazard Categories:

Immediate Heath: No
Delayed Health: No
Fire: No
Sudden Pressure: No
Reactivity: No

16. OTHER INFORMATION

REFERENCES:

1) Health Hazard Evaluation Summary for Sterile Diluent Lupron Depot (HHES Number: 1818.2), Abbott Laboratories, issued 06/09/98,

2) RETECS for toxicity data for d-mannitol.

Prepared By. Drug Safety Department Tap Pharmaceutical Products Inc.

<u>Disclaimer</u>: The information and recommendations contained herein are based upon tests believed to be reliable. However, TAP Pharmaceutical Products Inc., does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform with actual conditions of usage may be required. TAP Pharmaceutical Products Inc., assumes no responsibility for results obtained or for incidental or consequential damages arising from the use of these data. No freedom for infringement of any patent, copyright or trademark is to be inferred.

^{*}Superfund Amendmends and the Reauthorization Act.